Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program
Looking for contract opportunity help?
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
General Information
- Contract Opportunity Type: Solicitation (Original)
- Original Published Date: Apr 30, 2021 09:34 am CDT
- Original Date Offers Due: Jun 24, 2021 12:00 pm CDT
- Inactive Policy: Manual
- Original Inactive Date: Oct 30, 2021
- Initiative:
- None
Classification
- Original Set Aside:
- Product Service Code:
- NAICS Code:
- Place of Performance: San Antonio , TX 78230USA
Description
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: August 2021: The following drug classes/sub classes and agents will be reviewed:
Laxatives-Cathartics-Stool Softeners, SUB CLASS: Bowel Preparations: Calquence; Imbruvica; and Brukinsa
Leukemia and Lymphoma Agents, SUB CLASS: Bruton Tyrosine Kinase Inhibitors: Clenpiq; Colyte With Flavor Packets; Gavilyte-N; Gavilyte-C; Gavilyte-G; Golytely; Moviprep; Nulytely; Nulytely With Flavor Packs; Osmoprep; Plenvu; Prepopik; and Suprep
RFQ: The RFQ, including UF BPA and UF ADP appendices are attached herein. The historical utilization data including quantity dispensed and 30 day equivalents by mouth is also attached herein.
Pre-Proposal Teleconference: See part 2.4 and 2.5 of the RFQ. The pre-proposal teleconference agenda with dial-in information will be sent out via email after manufacturer R.S.V.P. with the RFQ point of contact.
RFQ point of contact: See Part 2.3 of the RFQ.
For additional information, search DoD Pharmacy and Therapeutics (P&T) Committee at http://www.health.mil/POD
Attachments/Links
Contact Information
Primary Point of Contact
- Madison Northen
- madison.r.northen.civ@mail.mil
Secondary Point of Contact
- Monroe Porter
- monroe.s.porter.ctr@mail.mil